Reports say Pfizer could produce about 1.3 billion doses by the end of 2021, if the vaccine is approved. Dado Ruvic / Reuters
The first patient enrolled in Pfizer's coronavirus vaccine trial at the University of Maryland School of Medicine receives his first shot in May 2020. On Monday, the drug maker said its Phase-3 trials showed it protected 90 per cent of recipients within 28 days of taking the jabs. AP
Pfizer's headquarters in New York. Shares in the drug maker rose sharply in pre-market trading as news of its breakthrough was released. AFP / Getty
Reports say Pfizer could produce about 1.3 billion doses by the end of 2021, if the vaccine is approved. Dado Ruvic / Reuters
Germany trial partner BionTech's headquarters in Mainz, Germany. EPA
Reports say Pfizer could produce about 1.3 billion doses by the end of 2021, if the vaccine is approved. Dado Ruvic / Reuters
The first patient enrolled in Pfizer's coronavirus vaccine trial at the University of Maryland School of Medicine receives his first shot in May 2020. On Monday, the drug maker said its Phase-3 trials showed it protected 90 per cent of recipients within 28 days of taking the jabs. AP
Pfizer's headquarters in New York. Shares in the drug maker rose sharply in pre-market trading as news of its breakthrough was released. AFP / Getty
Reports say Pfizer could produce about 1.3 billion doses by the end of 2021, if the vaccine is approved. Dado Ruvic / Reuters
Germany trial partner BionTech's headquarters in Mainz, Germany. EPA
Reports say Pfizer could produce about 1.3 billion doses by the end of 2021, if the vaccine is approved. Dado Ruvic / Reuters
